Together, these results from AHC-patient-derived iPSCs provide a proof-of-concept for efficient PE and ABE correction of mutations that account for a majority of known ATP1A3-associated AHC cases. This evidence concerns the gene ATP1A3 and alternating hemiplegia of childhood.